« BACK
Life Sciences - Pharmacology - 18.07.2019 
New prebiotics: benefits without the downsides?
Prebiotics are currently a preferred treatment for certain metabolic disorders, as they can restore the balance of dysfunctional gut microbiota, and improve the body's metabolism. However, these substances have to be used at high doses, which can result in patients experiencing bloating and flatulence.
Innovation / Technology - Pharmacology - 22.05.2019 
MaaT Pharma expands patent portfolio with three granted patents covering its microbiome restoration biotherapeutic platform
First patents to cover the fundamental processes for accessing the human gut microbiome as biotherapeutics. MaaT Pharma's microbiome sample collection and administration devices receive CE mark for use in collecting and administrating gut-derived samples as biotherapeutics to patients.
Life Sciences - Pharmacology - 21.12.2018 
A novel antibiotic resistance mechanism
Bacteria make use of a number of natural resistance strategies to overcome antibiotics. And it seems that this bacterial toolbox may be much more varied than previously thought. Scientists at the Institut Pasteur, in collaboration with Inserm, INRA, the CNRS and the Weizmann Institute of Science in Israel, have recently revealed an entirely unknown resistance mechanism in Listeria monocytogenes bacteria.
Pharmacology
Results 1 - 3 of 3.
Prebiotics are currently a preferred treatment for certain metabolic disorders, as they can restore the balance of dysfunctional gut microbiota, and improve the body's metabolism. However, these substances have to be used at high doses, which can result in patients experiencing bloating and flatulence.
First patents to cover the fundamental processes for accessing the human gut microbiome as biotherapeutics. MaaT Pharma's microbiome sample collection and administration devices receive CE mark for use in collecting and administrating gut-derived samples as biotherapeutics to patients.
Bacteria make use of a number of natural resistance strategies to overcome antibiotics. And it seems that this bacterial toolbox may be much more varied than previously thought. Scientists at the Institut Pasteur, in collaboration with Inserm, INRA, the CNRS and the Weizmann Institute of Science in Israel, have recently revealed an entirely unknown resistance mechanism in Listeria monocytogenes bacteria.